• Insulin and Oral Antidiabetic, Pramlintide
    Dosage form: Injection
    Strength: 0.6mg/ml, 1mg/ml
    Indications/Special comments: Type 1 and type 2 diabetes: Adjunct treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy.
    Dosage Administration: SC: Adults: Note: When initiating pramlintide, reduce current mealtime insulin dose (including premixed preparations) by 50% to avoid hypoglycaemia. If pramlintide is discontinued for any reason, restart therapy with same initial titration protocol. If a dose is missed, wait until the next scheduled dose and administer the usual amount. Type 1 diabetes mellitus: Initial: 15mcg immediately prior to major meals; titrate in 15mcg increments every 3 days (if no significant nausea occurs) to target dose of 30 to 60mcg prior to major meals (consider discontinuation if intolerant of 30mcg dose). Type 2 diabetes mellitus: Initial: 60mcg immediately prior to major meals; after 3 days, increase to 120mcg prior to each major meal if no significant nausea occurs (if nausea occurs at 120mcg dose, reduce to 60mcg). Subcutaneous: Do not mix with insulins; administer subcutaneously into abdominal or thigh areas at sites distinct from concomitant insulin injections (do not administer into arm due to variable absorption); rotate injection sites frequently. Allow solution to reach room temperature before administering; may reduce injection site reactions. For oral medications in which a rapid onset of action is desired, administer 1 hour before, or 2 hours after pramlintide, if possible.
    View full drug info
  • Insulin and Oral Antidiabetic, Pioglitazone
    Dosage form: Tablet
    Strength: 15mg, 30mg, 45mg
    Indications/Special comments: Type II diabetes mellitus (NIDDM), monotherapy: Adjunct to diet and exercise, to improve glycemic control Type II diabetes mellitus (NIDDM). Combination therapy with sulfonyl urea, metformin, or insulin: when diet, exercise, and a single agent alone does not result in adequate glycaemic control.
    Dosage Administration: Monotherapy: Initial: 15 - 30mg once daily; if response is inadequate, the dosage may be increased in increments up to 45mg once daily; maximum recommended dose: 45mg once daily. Combination therapy: Maximum recommended dose: 45mg/day; with sulphonylureas: Initial: 15 - 30mg once daily; with metformin: Initial: 15 - 30mg once daily; with insulin: Initial: 15 - 30mg once daily.
    View full drug info
  • Immunological Preparations, Pneumoccocal Vaccine
    Dosage form: Injection
    Strength: 25mcg /0.5ml
    Indications/Special comments: People at risk of developing serious pneumococcal infection, such as patients with chronic cardiac or pulmonary disease, and with illnesses or conditions known to predispose to pneumoccal infection (such as sickle cell disease, nephritic syndrome, previous splenectomy, multiple myeloma and Hodgkin's disease); also in immunocompromised patients, including those with HIV infection.
    Dosage Administration: SC or IM, 0.5ml.
    View full drug info
  • Hormonal Preparations, Progesterone
    Dosage form: Pessary
    Strength: 100mg with applicator
    Indications/Special comments: Part of ART for infertile women with progesterone deficiency (pessaries
    Dosage Administration: Premenstrual syndrome; Post-natal depression: By vagina, or by rectum. Adult: 200 – 800mg daily; doses above 200mg to be given in 2 divided doses; for premenstrual syndrome start on day 12 – 14 and continue until onset of menstruation (but not recommended); rectally, if barrier methods of contraception are used, in patients who have recently given birth or in those who suffer from vaginal infection or recurrent cystitis. Progesterone Insufficiency- Assisted Reproductive Technology (ART): Vaginal Insert:100mg administered vaginally two or three times daily starting at oocyte retrieval and continuing for up to 10 weeks total duration. Usual Adult Dose for Premature Labour: 100mg vaginal suppository daily, between 24 and 34 weeks of gestation.
    View full drug info
  • Hormonal Preparations, Progesterone
    Dosage form: Implant
    Strength: n/a
    Indications/Special comments: Used in prevention of pregnancy over a long time (up to 5 years).
    Dosage Administration: Contraception (no hormonal contraceptive use in previous month):By subdermal implantation: Females of childbearing potential: 1 implant inserted during first 5 days of cycle, implant should be removed within 3 years of insertion. Contraception (postpartum): By subdermal implantation: Females of childbearing potential: 1 implant to be inserted 21 – 28 days after delivery, 1 implant to be inserted after 28 days postpartum in breast-feeding mothers; implant should be removed within 3 years of insertion. Contraception following abortion or miscarriage in the second trimester: By subdermal implantation: Females of childbearing potential: 1 implant to be inserted 21 – 28 days after abortion or miscarriage, implant should be removed within 3 years of insertion. Contraception following abortion or miscarriage in the first trimester: By subdermal implantation: Females of childbearing potential: 1 implant to be inserted within 5 days, implant should be removed within 3 years of insertion. Contraception (changing from other hormonal contraceptive): By subdermal implantation: Females of childbearing potential: Implant should be removed within 3 years of insertion (consult product literature).
    View full drug info
  • Gastrointestinal System Agents, Psyllium
    Dosage form: Powder
    Strength: 3.4g
    Indications/Special comments: Constipation, especially in diverticular disease and irritable bowel syndrome, and when excessive straining at stool must be avoided
    Dosage Administration: Oral: Adult and Child (12 years and older): 30g given daily in divided doses of 2.5 - 7.5g per dose; Children 6 - 11 years old - 15g daily given in divided doses of 2.5 - 3.75g per dose.
    View full drug info
  • Gastrointestinal System Agents, Promethazine Hydrochloride
    Dosage form: Injection
    Strength: 25mg/ml, 50mg/2ml
    Indications/Special comments: Control of nausea, vomiting, and vertigo of various causes, as a sedative and hypnotic, and as a common ingredient of cough and cold preparations; also see notes above.
    Dosage Administration: IM or IV: Adult: 12.5 to 25mg every 4 hours as needed. Child (> 2 years of age): 0.25 to 0.5mg per Kg of body weight every 4 to 6 hours as needed.
    View full drug info
  • Gastrointestinal System Agents, Polyethlene Glycol (PEG)
    Dosage form: Powder
    Strength: n/a
    Indications/Special comments: For the treatment of occasional constipation. This product should be used for 2 weeks or less or as directed by a physician.
    Dosage Administration: The usual dose is 17 grams (about 1 heaping tablespoon or one sachet) of powder per day (or as directed by physician) in 4-8 ounces of water, juice, soda, coffee, or tea. Two to 4 days (48 to 96 hours) may be required to produce a bowel movement.
    View full drug info
  • Gastrointestinal System Agents, Pantoprazole
    Dosage form: Injection
    Strength: 40 mg
    Indications/Special comments: Helicobacter pylori eradication in combination with amoxicillin and clarithromycin; or in combination with clarithromycin and metronidazole. Benign gastric ulcer. Duodenal ulcer. Prophylaxis of NSAID-associated gastric ulcer in patients with an increased risk of gastroduodenal complications that require continued NSAID treatment. Prophylaxis of NSAID-associated duodenal ulcer in patients with an increased risk of gastroduodenal complications that require continued NSAID treatment. Gastro-oesophageal reflux disease. Zollinger–Ellison syndrome (and other hypersecretory conditions.
    Dosage Administration: Gastric/duodenal ulcer: By intravenous injection, or by intravenous infusion: Adult: 40mg daily until oral administration can be resumed, injection to be given over at least 2 minutes. Gastro-oesophageal reflux disease. By intravenous injection, or by intravenous infusion: 40mg daily until oral administration can be resumed, injection to be given over at least 2 minutes. Zollinger–Ellison Syndrome (and other hypersecretory conditions). Elderly: 40mg daily. By intravenous injection, or by intravenous infusion. Special note: For intravenous infusion pantoprazole, give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute 40mg with 10 mL sodium chloride 0.9% and dilute with 100 mL of infusion fluid; give 40mg over 15 minutes.
    View full drug info
  • Gastrointestinal System Agents, Pantoprazole
    Dosage form: Capsule
    Strength: 40mg
    Indications/Special comments: Helicobacter pylori eradication in combination with amoxicillin and clarithromycin; or in combination with clarithromycin and metronidazole. Benign gastric ulcer. Duodenal ulcer. Prophylaxis of NSAID-associated gastric ulcer in patients with an increased risk of gastroduodenal complications that require continued NSAID treatment. Prophylaxis of NSAID-associated duodenal ulcer in patients with an increased risk of gastroduodenal complications that require continued NSAID treatment. Gastro-oesophageal reflux disease. Zollinger–Ellison syndrome (and other hypersecretory conditions.
    Dosage Administration: Helicobacter pylori eradication in combination with amoxicillin and clarithromycin; or in combination with clarithromycin and metronidazole - Oral: Adult: 40mg twice daily. Benign gastric ulcer: Oral: Adult: 40mg daily for 8 weeks; increased if necessary up to 80mg daily, dose increased in severe cases. Gastric ulcer/Duodenal ulcer: Oral: Adult:40mg daily for 4 weeks; increased if necessary up to 80mg daily, dose increased in severe cases. Prophylaxis of NSAID-associated duodenal ulcer in patients with an increased risk of gastroduodenal complications that require continued NSAID treatment. Oral: Adult: 20mg daily. Gastro-oesophageal reflux disease. Oral: Adult: 20 – 80mg daily for 4 weeks, continued for further 4 weeks if not fully healed, dose to be taken in the morning; maintenance 20mg daily and increased to 40mg daily, increased only if symptoms return. Zollinger–Ellison Syndrome (and other hypersecretory conditions). Oral: Adult: Initially, 80mg daily (max. per dose 80mg), adjusted according to response. Elderly: 40mg daily.Oral: initially 80mg, alternatively 160mg in 2 divided doses, if rapid acid control required, then 80mg once daily (max. per dose 80mg), adjusted according to response.
    View full drug info